Literature DB >> 18218161

Bovine respiratory syncytial virus infection: immunopathogenic mechanisms.

Laurel J Gershwin1.   

Abstract

Bovine respiratory syncytial virus (BRSV) causes severe respiratory disease in young cattle. Much like the human respiratory syncytial virus, BRSV induces immunomodulation in the infected host, favoring a Th2 response. Several groups have demonstrated IgE responses to BRSV proteins during infection and particularly in response to vaccination with formalin-inactivated vaccine in the field and experimentally. Newer vaccine modalities that favor a shift to Th1 cytokine production have provided promising results. Infection with BRSV is a major contributor to the multi-pathogen disease, bovine respiratory disease complex. This review stresses the unique immunomodulatory aspects of BRSV infection, vaccination and its interaction with the host's immune system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18218161     DOI: 10.1017/S1466252307001405

Source DB:  PubMed          Journal:  Anim Health Res Rev        ISSN: 1466-2523            Impact factor:   2.615


  22 in total

Review 1.  Animal models of human respiratory syncytial virus disease.

Authors:  Reinout A Bem; Joseph B Domachowske; Helene F Rosenberg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

2.  Effect of abrupt weaning at housing on leukocyte distribution, functional activity of neutrophils, and acute phase protein response of beef calves.

Authors:  E M Lynch; B Earley; M McGee; S Doyle
Journal:  BMC Vet Res       Date:  2010-07-22       Impact factor: 2.741

3.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

4.  Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice.

Authors:  Caroline M Percopo; Zhijun Qiu; Simon Phipps; Paul S Foster; Joseph B Domachowske; Helene F Rosenberg
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

Review 5.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

6.  Elucidation of the Host Bronchial Lymph Node miRNA Transcriptome Response to Bovine Respiratory Syncytial Virus.

Authors:  Dayle Johnston; Bernadette Earley; Matthew S McCabe; Jaewoo Kim; Jeremy F Taylor; Ken Lemon; Michael McMenamy; Catherine Duffy; S Louise Cosby; Sinéad M Waters
Journal:  Front Genet       Date:  2021-04-22       Impact factor: 4.599

7.  Genes controlling vaccine responses and disease resistance to respiratory viral pathogens in cattle.

Authors:  Elizabeth J Glass; Rebecca Baxter; Richard J Leach; Oliver C Jann
Journal:  Vet Immunol Immunopathol       Date:  2011-05-07       Impact factor: 2.046

8.  Calf health from birth to weaning. III. housing and management of calf pneumonia.

Authors:  Ingrid Lorenz; Bernadette Earley; John Gilmore; Ian Hogan; Emer Kennedy; Simon J More
Journal:  Ir Vet J       Date:  2011-10-21       Impact factor: 2.146

9.  A randomized controlled trial comparing non-steroidal anti-inflammatory and fusion protein inhibitors singly and in combination on the histopathology of bovine respiratory syncytial virus infection.

Authors:  Francisco R Carvallo Chaigneau; Paul Walsh; Maxim Lebedev; Victoria Mutua; Heather McEligot; Heejung Bang; Laurel J Gershwin
Journal:  PLoS One       Date:  2021-06-10       Impact factor: 3.240

Review 10.  Neonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infants.

Authors:  Randy E Sacco; Jodi L McGill; Mitchell V Palmer; John D Lippolis; Timothy A Reinhardt; Brian J Nonnecke
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.